A Companion Cancer Diagnostics is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
This report aims to provide a comprehensive presentation of the global market for Companion Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Companion Cancer Diagnostics. This report contains market size and forecasts of Companion Cancer Diagnostics in global, including the following market information:
- Global Companion Cancer Diagnostics Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2022 (%)
The global Companion Cancer Diagnostics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Breast Cancer Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Companion Cancer Diagnostics include F. Hoffmann-La Roche, Agilent Technologies, QIAGEN, Abbott Laboratories, Almac Group, Danaher Corporation, bioM?rieuxSA and Myriad Genetics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Companion Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Companion Cancer Diagnostics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Companion Cancer Diagnostics Market Segment Percentages, by Type, 2022 (%)
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Gastric Cancer
Global Companion Cancer Diagnostics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Companion Cancer Diagnostics Market Segment Percentages, by Application, 2022 (%)
- Pharmaceutical & Biopharmaceutical Companies
- Reference Laboratories
- CROs
- Others
Global Companion Cancer Diagnostics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Companion Cancer Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Companion Cancer Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Companion Cancer Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- F. Hoffmann-La Roche
- Agilent Technologies
- QIAGEN
- Abbott Laboratories
- Almac Group
- Danaher Corporation
- bioM?rieuxSA
- Myriad Genetics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Companion Cancer Diagnostics, market overview.
Chapter 2: Global Companion Cancer Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Companion Cancer Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments
by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments
by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Companion Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Companion Cancer Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Companion Cancer Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Companion Cancer Diagnostics Overall Market Size
2.1 Global Companion Cancer Diagnostics Market Size: 2022 VS 2030
2.2 Global Companion Cancer Diagnostics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Companion Cancer Diagnostics Players in Global Market
3.2 Top Global Companion Cancer Diagnostics Companies Ranked by Revenue
3.3 Global Companion Cancer Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Companion Cancer Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Companion Cancer Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Companion Cancer Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Companion Cancer Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Companion Cancer Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Companion Cancer Diagnostics Market Size Markets, 2022 & 2030
4.1.2 Breast Cancer
4.1.3 Lung Cancer
4.1.4 Colorectal Cancer
4.1.5 Melanoma
4.1.6 Gastric Cancer
4.2 By Type - Global Companion Cancer Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Companion Cancer Diagnostics Revenue, 2018-2023
4.2.2 By Type - Global Companion Cancer Diagnostics Revenue, 2024-2030
4.2.3 By Type - Global Companion Cancer Diagnostics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Companion Cancer Diagnostics Market Size, 2022 & 2030
5.1.2 Pharmaceutical & Biopharmaceutical Companies
5.1.3 Reference Laboratories
5.1.4 CROs
5.1.5 Others
5.2 By Application - Global Companion Cancer Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Companion Cancer Diagnostics Revenue, 2018-2023
5.2.2 By Application - Global Companion Cancer Diagnostics Revenue, 2024-2030
5.2.3 By Application - Global Companion Cancer Diagnostics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Companion Cancer Diagnostics Market Size, 2022 & 2030
6.2 By Region - Global Companion Cancer Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Companion Cancer Diagnostics Revenue, 2018-2023
6.2.2 By Region - Global Companion Cancer Diagnostics Revenue, 2024-2030
6.2.3 By Region - Global Companion Cancer Diagnostics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Companion Cancer Diagnostics Revenue, 2018-2030
6.3.2 US Companion Cancer Diagnostics Market Size, 2018-2030
6.3.3 Canada Companion Cancer Diagnostics Market Size, 2018-2030
6.3.4 Mexico Companion Cancer Diagnostics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Companion Cancer Diagnostics Revenue, 2018-2030
6.4.2 Germany Companion Cancer Diagnostics Market Size, 2018-2030
6.4.3 France Companion Cancer Diagnostics Market Size, 2018-2030
6.4.4 U.K. Companion Cancer Diagnostics Market Size, 2018-2030
6.4.5 Italy Companion Cancer Diagnostics Market Size, 2018-2030
6.4.6 Russia Companion Cancer Diagnostics Market Size, 2018-2030
6.4.7 Nordic Countries Companion Cancer Diagnostics Market Size, 2018-2030
6.4.8 Benelux Companion Cancer Diagnostics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Companion Cancer Diagnostics Revenue, 2018-2030
6.5.2 China Companion Cancer Diagnostics Market Size, 2018-2030
6.5.3 Japan Companion Cancer Diagnostics Market Size, 2018-2030
6.5.4 South Korea Companion Cancer Diagnostics Market Size, 2018-2030
6.5.5 Southeast Asia Companion Cancer Diagnostics Market Size, 2018-2030
6.5.6 India Companion Cancer Diagnostics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Companion Cancer Diagnostics Revenue, 2018-2030
6.6.2 Brazil Companion Cancer Diagnostics Market Size, 2018-2030
6.6.3 Argentina Companion Cancer Diagnostics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Companion Cancer Diagnostics Revenue, 2018-2030
6.7.2 Turkey Companion Cancer Diagnostics Market Size, 2018-2030
6.7.3 Israel Companion Cancer Diagnostics Market Size, 2018-2030
6.7.4 Saudi Arabia Companion Cancer Diagnostics Market Size, 2018-2030
6.7.5 UAE Companion Cancer Diagnostics Market Size, 2018-2030
7 Companion Cancer Diagnostics Companies Profiles
7.1 F. Hoffmann-La Roche
7.1.1 F. Hoffmann-La Roche Company Summary
7.1.2 F. Hoffmann-La Roche Business Overview
7.1.3 F. Hoffmann-La Roche Companion Cancer Diagnostics Major Product Offerings
7.1.4 F. Hoffmann-La Roche Companion Cancer Diagnostics Revenue in Global Market (2018-2023)
7.1.5 F. Hoffmann-La Roche Key News & Latest Developments
7.2 Agilent Technologies
7.2.1 Agilent Technologies Company Summary
7.2.2 Agilent Technologies Business Overview
7.2.3 Agilent Technologies Companion Cancer Diagnostics Major Product Offerings
7.2.4 Agilent Technologies Companion Cancer Diagnostics Revenue in Global Market (2018-2023)
7.2.5 Agilent Technologies Key News & Latest Developments
7.3 QIAGEN
7.3.1 QIAGEN Company Summary
7.3.2 QIAGEN Business Overview
7.3.3 QIAGEN Companion Cancer Diagnostics Major Product Offerings
7.3.4 QIAGEN Companion Cancer Diagnostics Revenue in Global Market (2018-2023)
7.3.5 QIAGEN Key News & Latest Developments
7.4 Abbott Laboratories
7.4.1 Abbott Laboratories Company Summary
7.4.2 Abbott Laboratories Business Overview
7.4.3 Abbott Laboratories Companion Cancer Diagnostics Major Product Offerings
7.4.4 Abbott Laboratories Companion Cancer Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Abbott Laboratories Key News & Latest Developments
7.5 Almac Group
7.5.1 Almac Group Company Summary
7.5.2 Almac Group Business Overview
7.5.3 Almac Group Companion Cancer Diagnostics Major Product Offerings
7.5.4 Almac Group Companion Cancer Diagnostics Revenue in Global Market (2018-2023)
7.5.5 Almac Group Key News & Latest Developments
7.6 Danaher Corporation
7.6.1 Danaher Corporation Company Summary
7.6.2 Danaher Corporation Business Overview
7.6.3 Danaher Corporation Companion Cancer Diagnostics Major Product Offerings
7.6.4 Danaher Corporation Companion Cancer Diagnostics Revenue in Global Market (2018-2023)
7.6.5 Danaher Corporation Key News & Latest Developments
7.7 bioM?rieuxSA
7.7.1 bioM?rieuxSA Company Summary
7.7.2 bioM?rieuxSA Business Overview
7.7.3 bioM?rieuxSA Companion Cancer Diagnostics Major Product Offerings
7.7.4 bioM?rieuxSA Companion Cancer Diagnostics Revenue in Global Market (2018-2023)
7.7.5 bioM?rieuxSA Key News & Latest Developments
7.8 Myriad Genetics
7.8.1 Myriad Genetics Company Summary
7.8.2 Myriad Genetics Business Overview
7.8.3 Myriad Genetics Companion Cancer Diagnostics Major Product Offerings
7.8.4 Myriad Genetics Companion Cancer Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Myriad Genetics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Companion Cancer Diagnostics Market Opportunities & Trends in Global Market
Table 2. Companion Cancer Diagnostics Market Drivers in Global Market
Table 3. Companion Cancer Diagnostics Market Restraints in Global Market
Table 4. Key Players of Companion Cancer Diagnostics in Global Market
Table 5. Top Companion Cancer Diagnostics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Companion Cancer Diagnostics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Companion Cancer Diagnostics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Companion Cancer Diagnostics Product Type
Table 9. List of Global Tier 1 Companion Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Companion Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Companion Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Companion Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Companion Cancer Diagnostics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Companion Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Companion Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Companion Cancer Diagnostics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Companion Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Companion Cancer Diagnostics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Companion Cancer Diagnostics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Companion Cancer Diagnostics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Companion Cancer Diagnostics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Companion Cancer Diagnostics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Companion Cancer Diagnostics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Companion Cancer Diagnostics Revenue, (US$, Mn), 2024-2030
Table 30. F. Hoffmann-La Roche Company Summary
Table 31. F. Hoffmann-La Roche Companion Cancer Diagnostics Product Offerings
Table 32. F. Hoffmann-La Roche Companion Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 33. F. Hoffmann-La Roche Key News & Latest Developments
Table 34. Agilent Technologies Company Summary
Table 35. Agilent Technologies Companion Cancer Diagnostics Product Offerings
Table 36. Agilent Technologies Companion Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 37. Agilent Technologies Key News & Latest Developments
Table 38. QIAGEN Company Summary
Table 39. QIAGEN Companion Cancer Diagnostics Product Offerings
Table 40. QIAGEN Companion Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 41. QIAGEN Key News & Latest Developments
Table 42. Abbott Laboratories Company Summary
Table 43. Abbott Laboratories Companion Cancer Diagnostics Product Offerings
Table 44. Abbott Laboratories Companion Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 45. Abbott Laboratories Key News & Latest Developments
Table 46. Almac Group Company Summary
Table 47. Almac Group Companion Cancer Diagnostics Product Offerings
Table 48. Almac Group Companion Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 49. Almac Group Key News & Latest Developments
Table 50. Danaher Corporation Company Summary
Table 51. Danaher Corporation Companion Cancer Diagnostics Product Offerings
Table 52. Danaher Corporation Companion Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 53. Danaher Corporation Key News & Latest Developments
Table 54. bioM?rieuxSA Company Summary
Table 55. bioM?rieuxSA Companion Cancer Diagnostics Product Offerings
Table 56. bioM?rieuxSA Companion Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 57. bioM?rieuxSA Key News & Latest Developments
Table 58. Myriad Genetics Company Summary
Table 59. Myriad Genetics Companion Cancer Diagnostics Product Offerings
Table 60. Myriad Genetics Companion Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 61. Myriad Genetics Key News & Latest Developments
List of Figures
Figure 1. Companion Cancer Diagnostics Segment by Type in 2022
Figure 2. Companion Cancer Diagnostics Segment by Application in 2022
Figure 3. Global Companion Cancer Diagnostics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Companion Cancer Diagnostics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Companion Cancer Diagnostics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Companion Cancer Diagnostics Revenue in 2022
Figure 8. By Type - Global Companion Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Companion Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 10. By Type - Global Companion Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Companion Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 12. By Application - Global Companion Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Companion Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 14. By Region - Global Companion Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 15. By Country - North America Companion Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 16. US Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Companion Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 20. Germany Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 21. France Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Companion Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 28. China Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 32. India Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Companion Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 34. Brazil Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Companion Cancer Diagnostics Revenue Market Share, 2018-2030
Figure 37. Turkey Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Companion Cancer Diagnostics Revenue, (US$, Mn), 2018-2030
Figure 41. F. Hoffmann-La Roche Companion Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Agilent Technologies Companion Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. QIAGEN Companion Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Abbott Laboratories Companion Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Almac Group Companion Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Danaher Corporation Companion Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. bioM?rieuxSA Companion Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Myriad Genetics Companion Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
